L G Horvath
Overview
Explore the profile of L G Horvath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sutherland S, Ju X, Horvath L, Clark G
Front Immunol
. 2021 Apr;
12:641307.
PMID: 33854509
Tumors evade the immune system though a myriad of mechanisms. Using checkpoint inhibitors to help reprime T cells to recognize tumor has had great success in malignancies including melanoma, lung,...
2.
3.
Quinn D, Sandler H, Horvath L, Goldkorn A, Eastham J
Ann Oncol
. 2017 Oct;
28(11):2658-2669.
PMID: 29045523
Chemotherapy has been explored as a treatment option for metastatic prostate cancer since the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of men with metastatic castration-resistant...
4.
Zhang A, Grogan J, Mahon K, Rasiah K, Sved P, Eisinger D, et al.
Ann Oncol
. 2017 May;
28(8):1903-1909.
PMID: 28486686
Background: Prostate cancers (PCs) with similar characteristics at the time of diagnosis can have very different disease outcomes. Conventional biomarkers of PC still lack precision in identifying individuals at high...
5.
Lomax A, Beith J, Bhadri V, Boyer M, Grimison P, Horvath L, et al.
Intern Med J
. 2016 Aug;
46(12):1392-1398.
PMID: 27554283
Background: Immunotherapy agents show anti-cancer activity in several solid cancers. Efficacy in non-melanoma solid tumours for non-approved indications is unknown. Aim: To evaluate patient and disease characteristics, rate and duration...
6.
Mahon K, Lin H, Castillo L, Lee B, Lee-Ng M, Chatfield M, et al.
Br J Cancer
. 2015 Apr;
112(8):1340-8.
PMID: 25867259
Background: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance...
7.
Mahon K, Qu W, Devaney J, Paul C, Castillo L, Wykes R, et al.
Br J Cancer
. 2014 Aug;
111(9):1802-9.
PMID: 25144624
Background: Glutathione S-transferase 1 (GSTP1) inactivation is associated with CpG island promoter hypermethylation in the majority of prostate cancers (PCs). This study assessed whether the level of circulating methylated GSTP1...
8.
Lin H, Castillo L, Mahon K, Chiam K, Lee B, Nguyen Q, et al.
Br J Cancer
. 2014 Apr;
110(10):2462-71.
PMID: 24714754
Background: Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary...
9.
Yip P, Cooper W, Kohonen-Corish M, Lin B, McCaughan B, Boyer M, et al.
J Clin Pathol
. 2013 Nov;
67(4):333-40.
PMID: 24265323
Aims: To determine the prognostic significance of pAkt expression in order to identify high-risk stage IB patients with non-small cell lung cancer (NSCLC) in an exploratory study. Methods: We identified...
10.
Nagrial A, Chang D, Nguyen N, Johns A, Chantrill L, Humphris J, et al.
Br J Cancer
. 2013 Nov;
110(2):313-9.
PMID: 24263063
Background: Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. Elderly patients are under-represented in Phase III clinical trials, and as a consequence the efficacy of adjuvant therapy in...